Baader Bank Aktiengesellschaft Cuts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Baader Bank Aktiengesellschaft lessened its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 55.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,000 shares of the company's stock after selling 18,452 shares during the period. Baader Bank Aktiengesellschaft's holdings in Hims & Hers Health were worth $363,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HIMS. Genesee Capital Advisors LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at $889,000. Perigon Wealth Management LLC bought a new stake in Hims & Hers Health in the fourth quarter valued at $337,000. Pacer Advisors Inc. bought a new stake in Hims & Hers Health in the fourth quarter valued at $374,000. KBC Group NV increased its stake in Hims & Hers Health by 107.9% in the fourth quarter. KBC Group NV now owns 8,471 shares of the company's stock valued at $205,000 after purchasing an additional 4,396 shares in the last quarter. Finally, Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares in the company, valued at $6,206,821.32. This represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 27,098 shares of the company's stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $30.08, for a total value of $815,107.84. Following the sale, the chief executive officer now owns 27,918 shares in the company, valued at approximately $839,773.44. This represents a 49.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,256,067 shares of company stock worth $34,459,485. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 4.5 %

HIMS traded up $1.68 during trading hours on Monday, hitting $38.96. The stock had a trading volume of 16,241,378 shares, compared to its average volume of 10,688,618. Hims & Hers Health, Inc. has a 1 year low of $8.51 and a 1 year high of $39.74. The company's fifty day simple moving average is $29.20 and its 200 day simple moving average is $22.57. The stock has a market cap of $8.51 billion, a PE ratio of 88.44 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts' expectations of $382.20 million. During the same period in the previous year, the business posted ($0.04) EPS. The firm's quarterly revenue was up 77.1% compared to the same quarter last year. As a group, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on HIMS. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $42.00 price target for the company. BTIG Research began coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price for the company. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Citigroup lowered shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and upped their target price for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Finally, Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and lowered their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.